Keihanian Tara, Barkin Jodie A, Souto Enrico O
Department of Medicine, Division of Gastroenterology, University of Miami Miller School of Medicine, Miami, Florida.
Gastroenterol Hepatol (N Y). 2021 Jun;17(6):254-262.
Pancreatic cancer (PC) is expected to become the second leading cause of cancer-related mortality in the United States within the next decade. Patients often present at late stages of the disease, when they become symptomatic; in many cases, these patients have unresectable disease that is associated with a poor prognosis. Considering the low incidence of PC in the general population, routine screening of average-risk individuals is not feasible and not recommended. Individuals with familial germline mutations or familial PC are at higher risk of developing PC. Improving detection of PC at an earlier stage entails the recognition of high-risk individuals who may benefit from a long-term screening program. This article identifies patients who may be at increased risk of developing PC, discusses PC screening recommendations, and compares imaging-based modalities and biomarkers for early detection of PC.
胰腺癌(PC)预计在未来十年内将成为美国癌症相关死亡的第二大主要原因。患者通常在疾病晚期出现症状;在许多情况下,这些患者患有无法切除的疾病,预后较差。考虑到普通人群中PC的发病率较低,对平均风险个体进行常规筛查既不可行也不推荐。具有家族性种系突变或家族性PC的个体患PC的风险更高。更早地检测PC需要识别可能从长期筛查计划中受益的高危个体。本文确定了可能患PC风险增加的患者,讨论了PC筛查建议,并比较了基于成像的方法和用于早期检测PC的生物标志物。